Dangane da sakamakon kashi na biyu na binciken, haɗuwa da daidaitaccen magani na chemotherapy azacitidine da mai hanawa na rigakafi. nivolumab ( nivolumab) ya nuna cewa yawan amsawa da kuma dawo da marasa lafiya tare da koma baya ko kuma rashin karfin myeloid cutar sankarar bargo ( AML ) Yawan rayuwa yana da ban ƙarfafa.
Binciken ya bi marasa lafiya 70. Bayan matsakaita na layuka biyu na jiyya, AML ya sake dawowa ya ba da rahoton cikakken martani na 2% da cikakken amsawar 33%. Haɗin magungunan yana da amfani musamman ga marasa lafiya waɗanda ba su taɓa karɓar wakilan hypomethylation (HMA) kamar azacitidine ko decitabine ba, kuma yawan tasirin waɗannan marasa lafiya shine 22%.
Masu binciken sun ce samfuran kasusuwan da aka tattara kafin magani ya nuna cewa yawan hasashen kwayar CD3 da CD8 kafin jiyya ya fi haka. Musamman, CD3 yana da babban ƙwarewa da ƙayyadaddun ƙayyadaddun bayanai don hango hasashen amsa, yana nuna cewa za a iya amfani da shi azaman masanin kimiyyar masarufi don zaɓar marasa lafiya don wannan haɗin haɗin gwiwa. "
Jiyya ya haɗa da allurar azacitidine ta cikin jijiyoyin jiki ko kuma ta karkashin jiki da allurar nivolumab. Kodayake yawancin marasa lafiya an sami nasarar magance su, kashi 11% na marasa lafiya har yanzu suna da haɗari ko kuma yiwuwar illa ga rayuwa. Gabaɗaya rayuwar duk marasa lafiya shine watanni 6.3. Adadin rayuwar marasa lafiya tare da sake dawowa na farko shine watanni 10.6, wanda ya ninka adadin rayuwa da aka lura tare da azacitidine kadai a cikin marasa lafiya irin wannan a MD Anderson.
Mai bincike Daver ya ce binciken da ya dace na zamani na III yana gudana, kuma mun yi imanin cewa aiwatar da magungunan asibiti da na rigakafi don zaɓar marasa lafiya na iya haifar da ƙarin ci gaba a cikin waɗannan nau'ikan hanyoyin kwantar da hankali a cikin AML.
https://medicalxpress.com/news/2018-11-combination-chemotherapy-immunotherapy-effective-phase.html
